Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial

Pettitt, AR, Jackson, R, Cicconi, S et al. (23 more authors) (2020) Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial. Haematologica, 105 (12). pp. 2868-2871. ISSN 0390-6078

Metadata

Authors/Creators:
  • Pettitt, AR
  • Jackson, R
  • Cicconi, S
  • Polydoros, F
  • Yap, C
  • Dodd, J
  • Bickerstaff, M
  • Stackpoole, M
  • Khan, UT
  • Carruthers, S
  • Oates, M
  • Lin, K
  • Coupland, SE
  • Menon, G
  • Kalakonda, N
  • McCarthy, H
  • Bloor, A
  • Schuh, A
  • Duncombe, A
  • Dearden, C
  • Fegan, C
  • Kennedy, B
  • Walewska, R
  • Marshall, S
  • Fox, CP
  • Hillmen, P ORCID logo https://orcid.org/0000-0001-5617-4403
Copyright, Publisher and Additional Information: (c) 2020 Ferrata Storti Foundation. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dates:
  • Published: December 2020
  • Accepted: 7 February 2020
  • Published (online): 13 February 2020
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 19 Feb 2020 13:02
Last Modified: 08 Jan 2021 16:20
Status: Published
Publisher: Ferrata Storti Foundation
Identification Number: https://doi.org/10.3324/haematol.2019.230805

Share / Export

Statistics